|
Indications and Dosage
Oral
Prophylaxis of influenza A Adult: 100 mg bid. Child: 1-9 years 5mg/kg daily in 1 or 2 divided doses. Max: 150 mg daily. ≥10 years Same as adult dose. Elderly: 100 mg daily. Oral Influenza A Adult: 100 mg bid for 7 days.
Elderly: 100 mg daily. |
||||
|
Renal Impairment
|
||||
|
Hepatic Impairment
Severe: 100 mg daily.
|
||||
|
Contraindications
Hypersensitivity.
|
||||
|
Special Precautions
Patient with a history of seizure disorder. Elderly. Hepatic and renal impairment. Pregnancy and lactation.
|
||||
|
Adverse Reactions
Significant: Seizure.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, xerostomia. General disorders and administration site conditions: Fatigue. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Headache, dizziness. Psychiatric disorders: Insomnia, nervousness. |
||||
|
Monitoring Parameters
Assess the elderly, or patients with hepatic or renal impairment for CNS or gastrointestinal adverse effects.
|
||||
|
Drug Interactions
Decreased plasma concentrations with paracetamol and aspirin. May diminish the therapeutic effect of influenza virus vaccines.
|
||||
|
Action
Description: Rimantadine, an adamantane derivative, synthetic antiviral agent that exerts its effect on influenza A virus (H1N1, H2N2, H3N2) early in the viral replicative cycle which possibly inhibits the uncoating of the virus.
Pharmacokinetics: Absorption: Well absorbed from the gastrointestinal tract. Time to peak plasma concentration: 6 hours. Distribution: Volume of distribution: 727-728 L. Plasma protein binding: Approx 40%, mainly to albumin. Metabolism: Metabolised in the liver via hydroxylation and glucuronidation. Excretion: Via urine (<25% as unchanged drug). Elimination half-life: 25.4 hours (range: 13-65 hours). |
||||
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5071, Rimantadine. https://pubchem.ncbi.nlm.nih.gov/compound/Rimantadine. Accessed Nov. 25, 2020. |
||||
|
Storage
Store at 25°C.
|
||||
|
MIMS Class
|
||||
|
ATC Classification
J05AC02 - rimantadine ; Belongs to the class of thiosemicarbazone antivirals. Used in the systemic treatment of viral infections.
|
||||
|
References
Anon. Rimantadine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 22/10/2020. Anon. Rimantadine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 22/10/2020. Buckingham R (ed). Rimantadine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/10/2020. Rimantadine Hydrochloride Tablet, Film Coated (Amneal Pharmaceuticals of New York LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 22/10/2020.
|
Sign Out
